Novavax announced initial Omicron cross-reactivity data from COVID-19 vaccine booster and adolescent studies
On Dec. 22, 2021, Novavax announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against…
-
-
Pfizer received U.S. FDA Emergency Use Authorization for novel COVID-19 oral antiviral treatment
On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
-
Gilead announced NEJM publication of data demonstrating Veklury (Remdesivir) significantly reduced risk of hospitalization in patients with COVID-19
On Dec. 22, 2021, Gilead Sciences announced full results from a Phase 3 investigational study evaluating the efficacy…
-
Oxford team published blueprint for making millions of doses of a new vaccine within 100 days
On Dec. 21, 2021, the University of Oxford’s vaccine manufacturing research team published a pre-print paper demonstrating the…
-
EC expanded indication for Veklury (Remdesivir) for treatment of adults not on supplemental oxygen and high risk for COVID-19 progression
On Oct. 21, 2021, Gilead Sciences announced that the European Commission (EC) had approved a variation to the…
-
USDA confirmed COVID-19 in a Canada lynx at a Pennsylvania zoo
On Dec. 21, 2021, the United States Department of Agriculture’s (USDA) National Veterinary Services Laboratories announced confirmation of…
-
Novavax announced initiation of PREVENT-19 COVID-19 vaccine phase 3 trial booster study
On Dec. 21, 2021, Novavax announced that the first booster doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based…
-
Oragenics extended collaboration with the National Research Council of Canada (NRC) to develop vaccine against Omicron variant
On Dec. 20, 2021, Oragenics announced it had extended a licensing and collaboration agreement with the National Research…
-
World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
-
European Commission granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the European Commission (EC) had granted Novavax conditional marketing authorization (CMA)…
-
Moderna announced preliminary booster data and updated strategy to address Omicron variant
On Dec. 20, 2021, Moderna announced preliminary neutralizing antibody data against the Omicron variant following the Company’s booster…
-
Pfizer and BioNTech provided EU more than 200 million additional doses of COMIRNATY for vaccine supply
On Dec. 20, 2021, Pfizer and BioNTech announced an agreement had been reached with the European Commission (EC)…
-
Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
-
NIH scientists urged pursuit of universal coronavirus vaccine
On Dec. 16, 2021, NIH scientists announced that to counter future coronavirus outbreaks, the global scientific and medical…
-
Democratic Republic of the Congo declared Ebola outbreak over
On Dec. 16, 2021, the Ebola outbreak that erupted in the Democratic Republic of the Congo’s North Kivu…
-
Merck and Ridgeback published phase 3 study of Molnupiravir, investigational oral antiviral COVID-19 treatment, in NEJM
On Dec. 16, 2021, Merck and Ridgeback Biotherapeutics announced the New England Journal of Medicine had published findings…
-
Johnson & Johnson announced positive CHMP opinion for a booster shot of its COVID-19 vaccine
On Dec. 15, 2021, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Twist Bioscience began shipping synthetic RNA positive controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 variant for Development of Accurate Diagnostic Tests
On Dec. 15, 2021, Twist Bioscience announced that synthetic RNA positive controls were available for the SARS-CoV-2 Omicron…
-
Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine
On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…
-
NRx Pharma announced new, favorable safety report for ZYESAMIﾮ (aviptadil) in NIH sponsored ACTIV-3b critical care study in patients with COVID-19
On Dec. 14, 2021, NRx Pharmaceuticals provided a new safety update on ZYESAMIﾮ (aviptadil), which was being tested…
-
Military Health System marked 1-year anniversary for COVID vaccinations
One year ago, on Dec. 14, 2020, the Military Health System began administering the first COVID-19 vaccine shots….
-
HHS released $9 billion in provider relief fund payments to support health care providers affected by COVID-19 Pandemic
On Dec. 12, 2021, the U.S. Department of Health and Human Services (HHS) announced the distribution of approximately…
-
Pfizer announced additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
-
Novavax filed for Emergency Use of COVID-19 vaccine in the United Arab Emirates
On Dec. 13, 2021, Novavax announced that it had submitted a regulatory filing to the Ministry of Health…
-
Moderna and Australia announced collaboration to bring mRNA manufacturing to Australia
On Dec. 13, 2021, Moderna announced an agreement with the Australian Government to build a state-of-the-art messenger RNA…
-
Vaccines shown to induce lower levels of neutralising antibodies against Omicron coronavirus variant
On Dec. 13, 2021, researchers from the University of Oxford analysed the impact of the Omicron COVID-19 variant…
-
CEPI partnered with Affinivax to develop a novel COVID-19 vaccine to target variants
On Dec. 13, 2021, the Coalition for Epidemic Preparedness Innovations, and Affinivax announced a partnership to advance the…
-
Biotechnology | COVID-19 | Vaccine | WHO
World Health Organization announced interim recommendations for use of the Janssen Ad26.COV2.S vaccine
On Dec. 10, 2021, the World Health Organization announced interim recommendations for the use of the Janssen Ad26.COV2.S…
-
Moderna announced additional 20 million doses of COVID-19 vaccine to COVAX for supply in 2021 and additional supply for 2022
On Dec. 10, 2021, Moderna announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to…
-
Pfizer and BioNTech received U.S. FDA EUA of COVID-19 vaccine booster for individuals 16 years and older
On Dec. 9, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
